Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Total Liabilities (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Total Liabilities for 17 consecutive years, with $22.4 million as the latest value for Q1 2026.

  • Quarterly Total Liabilities rose 31.31% to $22.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $22.4 million through Mar 2026, up 31.31% year-over-year, with the annual reading at $20.3 million for FY2025, 14.31% up from the prior year.
  • Total Liabilities for Q1 2026 was $22.4 million at Achieve Life Sciences, up from $20.3 million in the prior quarter.
  • The five-year high for Total Liabilities was $22.7 million in Q3 2022, with the low at $16.5 million in Q3 2024.
  • Average Total Liabilities over 5 years is $19.9 million, with a median of $20.3 million recorded in 2023.
  • The sharpest move saw Total Liabilities soared 631.82% in 2022, then dropped 23.28% in 2025.
  • Achieve Life Sciences' Total Liabilities stood at $21.7 million in 2022, then decreased by 3.92% to $20.8 million in 2023, then fell by 14.82% to $17.7 million in 2024, then rose by 14.31% to $20.3 million in 2025, then rose by 10.63% to $22.4 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Total Liabilities are $22.4 million (Q1 2026), $20.3 million (Q4 2025), and $18.4 million (Q3 2025).